Calidi Biotherapeutics To Present New Data On Its Approach Of Simultaneously Activating T-Cells At American Association Of Cancer Research Annual Meeting

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) will present new data on its T-cell activation approach at the American Association of Cancer Research annual meeting from April 17-22, 2026. The company is utilizing its RedTail virotherapy platform to target tumors and enhance therapeutic genetic payloads in the tumor microenvironment. Calidi's lead candidate, CLD-401, aims to express high levels of IL-15 SA in situ and is expected to have an IND filed by the end of 2026.